Vir Biotechnology (NASDAQ:VIR) EVP Sells $29,705.01 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 3,117 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $9.53, for a total transaction of $29,705.01. Following the transaction, the executive vice president directly owned 126,682 shares of the company’s stock, valued at $1,207,279.46. The trade was a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Verneuil Vanina De also recently made the following trade(s):

• On Wednesday, February 25th, Verneuil Vanina De sold 13,700 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.82, for a total transaction of $134,534.00.
• On Monday, February 23rd, Verneuil Vanina De sold 4,445 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total transaction of $33,115.25.

Vir Biotechnology Trading Down 2.5%

Shares of VIR stock opened at $9.09 on Friday. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $10.94. The stock has a market capitalization of $1.27 billion, a P/E ratio of -2.88 and a beta of 1.69. The firm’s 50 day moving average is $7.01 and its 200 day moving average is $6.08.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.11. The firm had revenue of $64.07 million for the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company’s revenue was up 417.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.76) EPS. As a group, equities analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Key Headlines Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas agreed to a collaboration on Vir’s prostate‑cancer asset (VIR‑5500) that includes up‑front and potential milestone payments totaling up to ~$1.7B, materially de‑risking that program and improving commercialization prospects. Read More.
• Positive Sentiment: Q4 results surprised to the upside: EPS and roughly $64M revenue beat consensus, signaling stronger commercial traction and likely underpinning recent analyst optimism. Read More.
• Positive Sentiment: Analysts have raised targets and ratings following the results and deal flow (Needham moved its target to $18), supporting upside from fundamentals despite volatility. Read More.
• Neutral Sentiment: Management will present at TD Cowen and Leerink in early March — useful for additional color and Q&A but not an immediate earnings/cash catalyst. Read More.
• Neutral Sentiment: Increased media/peer comparisons (head‑to‑head coverage) have raised visibility and trading volume; this can amplify moves but doesn’t change Vir’s underlying cashflow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross), which strengthens the balance sheet but is dilutive and increased near‑term share supply — a clear short‑term negative for the stock. Read More.
• Negative Sentiment: Market coverage singled out the discounted offering as the proximate cause of the post‑rally pullback, triggering selling and higher volatility. Read More.
• Negative Sentiment: Multiple insider sales were disclosed last week (including CEO and other senior officers/directors), increasing visible supply and feeding negative sentiment alongside the offering. Individual filings and summaries are available in SEC/insider reports. Read More.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Vir Biotechnology by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after acquiring an additional 1,390 shares during the period. FNY Investment Advisers LLC bought a new position in shares of Vir Biotechnology in the third quarter worth about $38,000. Raymond James Financial Inc. purchased a new stake in shares of Vir Biotechnology during the second quarter worth about $35,000. UMB Bank n.a. raised its stake in Vir Biotechnology by 1,418.7% during the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after purchasing an additional 6,597 shares during the period. Finally, Federated Hermes Inc. raised its stake in Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after purchasing an additional 4,899 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday. Leerink Partners reissued an “outperform” rating and issued a $20.00 price objective on shares of Vir Biotechnology in a report on Thursday. Evercore restated an “outperform” rating and set a $18.00 target price on shares of Vir Biotechnology in a research report on Tuesday. Needham & Company LLC increased their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Finally, Morgan Stanley lifted their price target on shares of Vir Biotechnology from $20.00 to $24.00 and gave the stock an “overweight” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.89.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.